List of Biologics Companies in Maryland - 101

AAVnerGene Inc is an innovative company specialized in AAV technologies. It is founded by a group of AAV gene therapy enthusiasts who dream to serve the community, promote and lead the future of gene therapy. Our passion is to solve the bottleneck problems in AAV gene therapy and find more and better cures for all the patients. We believe that hard core technologies are the key to achieve it. With 20 years of frontline gene therapy experience, our team develops novel AAV vectors, methods and strategies that can efficiently produce, deliver and express high quality vectors into specific cells. Our goal is to increase AAV gene therapy efficacy and decrease the cost, making it accessible and affordable to patients. Our highly complex AAV capsid libraries allow us to efficiently select the best AAV capsid for each cell type in a high-throughput manner.

Our mission is to make you stronger. The company was founded by a family directly impacted by three muscle wasting diseases: Duchenne muscular dystrophy, cancer cachexia and COPD. Our fight is personal and our commitment to developing better and more effective therapies is undaunted. AVGN7 prevents muscle wasting in different animal models and can restore muscle mass and strength even after wasting has already occurred. It works when injected directly into muscle or when administered systemically to all muscles. It was also designed to avoid the potentially serious side-effects of other "myostatin attenuating" therapies. AVGN7 for the durable maintenance of muscle mass and function.

AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

At Addimmune, our mission is to deliver the world’s first functional cure for HIV. Using viral vector delivery, we are seeking to give the immune system the tools it needs to resist and ultimately clear the virus.

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world’s most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients’ team – helping them advance today’s ideas into tomorrow’s medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

AgeneBio, Inc., is an emerging pharmaceutical company dedicated to developing innovative therapeutics that prevent neurodegeneration and preserve and restore cognitive function for unserved patients battling amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of aMCI. If approved, AgeneBio’s Phase 3-ready lead candidate, AGB101, will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. Learn more at www.agenebio.com and follow us on Twitter @AgeneBio.

Aloe Therapeutics is a biotech start-up aimed at delivering cancer cures. We have designed a therapy, termed Allo-Immunotherapy (AIM), to trigger an influx of activated immune cells to traffic to the tumor microenvironment - turning "cold" tumors "hot" and "hot" tumors "hotter." INFLAME WITH AIM.

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). P

American Gene Technologies® International Inc. (AGT™) is a private biotechnology company pursuing cures and treatments for infectious diseases, cancers, and monogenic disorders. AGT™'s emerging gene and cell therapeutics programs are designed to: ✅ Create immunotherapy for HIV disease with gene-modified T cells ✅ Activate innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology ✅ Treat PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation ✅ Advance clinically to provide human proof of concept For over a decade, AGT™ has developed, tested, and banked thousands of lentiviral vectors that can be adapted to the specific needs of new target diseases. AGT™ has developed gene therapy for diseases using this rapid gene delivery platform. GENE THERAPIES AGT™’s platform allows it to pursue clinical “cures” for complex diseases. The company has developed patent-protected gene therapeutics that are breakthroughs in medicine. *** See our extensive award winning patents on our website *** HIV/AIDS Immunotherapy for HIV disease with gene-modified T cells IMMUNO-ONCOLOGY Activates innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology PHENYLKETONURIA (PKU) Treats PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation AGT™'s Core Objectives ✔️ Leverage our lentivirus platform to create highly-effective targeted genetic medicines ✔️ Create solutions for patients across a spectrum of infectious diseases, cancers and inherited disorders ✔️ Collaborate with leading medical researchers from around the globe To learn more and get in touch with American Gene Technologies® Inc., contact us today at https://www.americangene.com/contact-us/

The American Society of Human Genetics (ASHG), founded in 1948, is the primary professional membership organization for human genetics specialists worldwide. The Society’s nearly 8,000 members include researchers, academicians, clinicians, laboratory practice professionals, genetic counselors, nurses and others who have a special interest in the field of human genetics. Our members work in a wide range of settings, including universities, hospitals, institutes, and medical and research laboratories. Our mission is to advance human genetics in science, health, and society through excellence in research, education, and advocacy. ASHG serves research scientists, health professionals, and the public by providing forums to: -- Share research results at annual meetings and in The American Journal of Human Genetics -- Advance genetic research by advocating for research support -- Enhance genetics education by preparing future professionals and informing the public -- Promote genetic services and support responsible social and scientific policies Connect with ASHG members and the broader human genetics community in our LinkedIn Group: https://www.linkedin.com/groups/142742

Amivas (US), LLC is an Australian, Canadian, and US joint venture focused on the development, manufacturing, and commercialization of therapeutics for the treatment of infectious diseases. Amivas (US), LLC was formed in response to the urgent need for a US -based firm to assume responsibility for the manufacture and distribution of Artesunate for Injection, for severe malaria after quinidine gluconate was discontinued by the manufacturer. With FDA approval of its first commercial product, Amivas (US), LLC is proud to join the global effort to fight and eradicate malaria.

Amplo Biotechnology is a private Gene Therapy company focusing on therapy for diseases of the neuromuscular junction.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company’s lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

AscentGene is a biotechnology company that provides high-quality cell lines and protein services to the life sciences community.

AsclepiX Therapeutics is focused on transforming the treatment of ocular diseases through the rapid clinical development of groundbreaking therapies aimed at empowering patients and their families around the world with the freedom to live their best lives. Using pioneering computational biology methods, we have identified multiple families of peptides that are potent regulators of vascular homeostasis. Our clinical candidates are derived from these peptides and work through naturally existing, highly evolved, and self-regulating mechanisms of homeostasis that maintain our health and well-being.

Autonomous Therapeutics is a synthetic immunology company developing artificial immune systems that are personalized and variant-proof. Encrypted RNA™ is a new class of RNA that enables variant-proof immunity against infectious diseases and cancers.

Avalo Therapeutics Inc. (Name changed from Cerecor Inc.) is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. We are a Delaware corporation, organized in April 2011 in partnership with various laboratories and research institutes at Johns Hopkins Medical Institute ("JHMI"​). Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. We acquire rights to early stage therapeutic technologies ("assets"​) from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.

BioFactura develops and commercializes biodefense drugs, novel drugs, and high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal choice for bringing these products to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer. As a result of BMI’s elucidation of “Deceptive Imprinting,” a mechanism of antigenic variation used by microbial pathogens and cancer cells to evade the host immune system, BMI developed “Immune Refocusing Technology” to circumvent such evasion mechanisms. Through the application of IRT, BMI strives to: (1) generate vaccines against pathogens for which no effective vaccine exists and (2) improve upon current strain-limited or serotype-limited protection of commercially available human and veterinary vaccines. IRT is able to alter the natural antigenicity and immunogenicity of targeted protein antigens making it a valuable tool to induce and select monoclonal antibodies. IRT can also be utilized to immune dampen therapeutic proteins and biologics to improve biological half-life and safety profiles.

Biologics Resources, LLC (BRLLC) is a Vaccines, immunotherapeutics and Biopharmaceuticals technology company.

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

BiOneCure Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative ADC drugs for the treatment of cancers. The company was founded in 2017 by a group of industry veterans who have worked in global biopharmaceutical companies. Their research focuses on creating innovative technology platforms and adopting a multifaceted approach to develop new medicines that exceed current standards. The current pipeline covers classic ADCs, bispecific ADCs, and bifunctional ADCs, aiming to be the first-in-class or the best-in-class products.

Cartesian Therapeutics is a fully integrated, clinical-stage biopharmaceutical company developing novel cell and gene immunotherapies to treat cancer and autoimmune diseases.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited; Juventas Cell Therapy Ltd.; Pharmathen Global BV; and Cleave Therapeutics, Inc. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.

Cellex has developed a rapid test for IgG and IgM antibodies to SARS-CoV-2. The company hastests that detect antibodies to multiple kinds of pathogens including HIV, HCV, Syphilis, HSV, and also makes tests for diabetes.Cellex received emergency use authorization (EUA) for its COVID-19 antibody test from the FDA for qSARS-CoV-2 IgG/IgM Rapid Test in 3/2020

Cellomics Technology, LLC is dedicated in developing more efficient and powerful tools to enhance and accelerate life science researches. Top scientific excellence is the goal and focus of our scientists.

Cellphire Therapeutics, Inc. is a Rockville, Maryland-based biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product, Thrombosomes®, a freeze-dried hemostatic agent derived from human platelets, is currently in a Phase I clinical trial. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine.

CentryMed is a biopharmaceutical company located in Frederick, Maryland, neighboring the National Cancer Institute (NCI) and numerous pioneering biotechnology companies and supporting entities. Since its founding in 2018, CentryMed has been dedicated to discovering and developing safer and more effective biotherapeutics for the treatment of various diseases.

Cerium Pharmaceuticals is dedicated to creating efficacious therapies for patients with kidney diseases. Cerium is currently focused on developing the first drug approved for a very rare kidney disease called Primary Membranous Nephropathy (PMN). There are approximately 75,000 PMN patients in the US and approximately 3,000 newly diagnosed PMN patients per year.

CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.

Cognate BioServices is a leading contract development and manufacturing organization specialized in cell and cell-mediated gene therapies. We pride ourselves in the level of quality and experience we bring to the table. Cognate is a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies, organizations and institutions. Cognate provides a unique combination of custom services to companies across all points of clinical and commercial development ranging from early preclinical studies, to mid phase trials and product scale-up though later stage clinical trials and bridging into commercial manufacturing. Cognate applies the know-how and expertise of its business, scientific and technical teams to successfully develop autologous and allogeneic products across multiple cell-based technology platforms from start to finish.

The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for people with cystic fibrosis, a rare, genetic disease in which a defective gene causes a thick buildup of mucus in the lungs, pancreas, and other organs. The buildup of mucus can lead to extensive lung damage, respiratory failure, malnutrition, liver disease, and gastrointestinal issues, among many other complications. Recognized globally, the Cystic Fibrosis Foundation has led the way in the fight against cystic fibrosis, fueling extraordinary medical and scientific progress. Working alongside the CF community, the CF Foundation has fostered the development of more than a dozen CF treatments — an unprecedented number in a short span of time — and helped add decades of life for people with CF. Thanks to this work, the life expectancy of someone born with CF has doubled in the last 30 years. We are driven by a dream that one day every person with cystic fibrosis will have the chance to live a long, healthy life. Our vision is a cure for every person with cystic fibrosis and a life free from the burden of this disease. While our headquarters are in Bethesda, Maryland, we have additional offices in more than 60 locations across the country with positions in fundraising, marketing, digital, information technology, legal, finance and more – all supporting our mission to cure cystic fibrosis. At the Foundation, we are committed to creating an environment that is free from discrimination and provides a rewarding experience for all members of our team. We strive to be an organization where everyone is welcomed and where talented individuals from all backgrounds have the opportunity to thrive. The CF Foundation is a nonprofit, donor-supported organization and an accredited charity of the Better Business Bureau's Wise Giving Alliance. Please visit us at www.cff.org.

D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers.

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

GDIT is a global technology and professional services company that delivers consulting, technology and mission services to every major agency across the U.S. government, defense and intelligence community. Our 30,000 experts extract the power of technology to create immediate value and deliver solutions at the edge of innovation. We operate across 30 countries worldwide, offering leading capabilities in digital modernization, AI/ML, Cloud, Cyber and application development. GDIT is part of General Dynamics, a global aerospace and defense company. We have shared our clients’ sense of purpose for over half a century and have a have a unique understanding of their missions, complex environments, and a rapidly changing world. Together with our clients, we strive to create a safer, smarter world by harnessing the power of deep expertise and advanced technology.

Elixirgen Scientific is a global leader in regenerative medicine and biotechnology, headquartered in the Science + Technology Park at the Johns Hopkins Medical Campus in Baltimore, MD. Our mission is to advance science and medicine with fast, functional, and scalable induced pluripotent stem cell (iPSC) differentiation products and services. Our state-of-the-art, transcription-factor-based technology allows you to overcome the high cost and inefficiencies associated with lengthy cell differentiation periods. We empower research institutions, pharmaceutical organizations, and biomedical enterprises worldwide, even those with no previous iPSC experience, by increasing access to relevant cells for modeling human biology and accelerating the path to drug discovery and development. This commitment to innovation and efficiency underpins our goal to revolutionize regenerative medicine. We are the partner of choice for supplying high-quality, reliable iPSC-derived cells and kits and conducting customized research services. Connect with Elixirgen Scientific today to discover how we can accelerate your research!

Elixirgen Therapeutics is a biotechnology company advancing its controllable self-replicating RNA technology to develop therapies for a broad spectrum of diseases, including rare diseases, aging-related disorders, and cancer. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore.

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

EMIT Imaging is the leading manufacturer of CFT systems and provider of CFT fee-for-service research for the global life sciences market. CFT was created to better visualize drug distribution and protein expression (pharmacokinetics/PK, and pharmacodynamics/PD) in whole animals at high resolution and sensitivity. CFT applications span drug discovery and delivery, oncology and immunotherapy, gene and cell therapy, neuroscience, and beyond. The company is based in Baltimore, MD, and Boston, MA.

ExeGi Pharma is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. Our team leverages the field of microbiome science to deliver novel, clinically supported, live biotherapeutic and probiotic treatments for a variety of unmet medical needs for both humans and veterinary applications. Makers of Visbiome and Visbiome Vet high potency probiotics.

Eyedea Medical develops new technologies to address the evolving needs of patients, corneal specialists, and eye banks. We provide affordable, high-quality products to improve the efficiency, quality, and accessibility of corneal transplants.

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. The company offers bioconjugation, protein expression, purification, immunoassay design, analytics, training, and consulting services.

Fzata, Inc. is a oral biologics biopharmaceutical company based in Halethorpe, MD within the vibrant BioHealth Capital Region. Fzata’s vision is to reduce health inequities by expanding patient access to therapeutic biologics. This is made possible with our proprietary first-in-class oral Bioengineered Probiotic Yeast Medicines (BioPYM™) platform. BioPYM enables orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, and more. Our oral biologic drug candidates are intended to help patients that inject biologic medicine by 1) offering affordable, non-refrigerated, convenient oral capsules, 2) improving quality of life with no needles and no need for health-care administration and 3) improving patient outcomes with expected high safety and high efficacy targeted to GI.

Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.

Gliknik is a privately held biopharmaceutical company working to ease human suffering by creating new therapies for people living with immune disorders.

Hememics uniquely uses graphene-based sensors with our patented bio preservatives to bring handheld, lab-quality testing performance to wherever needed – whether it is a farm, emergency room or battlefield. Our rugged, low-cost platform consists of a portable, easy-to-use reader utilizing a single-use biochip with 32 sensors. Our sensors can be individually programmed to detect molecular, antigen and antibody targets. We put a whole lab in your hand so you can make decisions when and wherever necessary – simplifying workflows with results within minutes.

Howard Hughes Medical Institute is a biomedical research organization focusing on advancing medical and life sciences research.

HypOxygen® was founded to provide technology with the level of precision and accuracy necessary for scientific study and research. We specialize in hypoxic chambers (or low oxygen incubators) for scientists focusing on cell research applications requiring precise atmospheric conditions that can be accurately controlled. Unlike a commonly used CO2 incubator, our hypoxia workstations can achieve these precise conditions.

Headquartered in North Bethesda, Maryland, Ibex Biosciences, Inc. ("Ibex") distinguishes itself in the early-stage biotech sector with its varied research and development approach. ​Ibex boasts a diverse portfolio that includes therapeutic antibodies, gene therapies, and regenerative medicine programs. We are proud of our proven capacity to discover and validate potential therapies from scratch, thus eliminating the need for external technology acquisitions or in-licensing. Our accomplishments are underscored by a series of in-vivo studies, which have delivered remarkable efficacy against a range of challenging medical conditions.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.

Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. ICT has established a broad portfolio of CAR-T products to treat cancer patients. Some highlights of the company are provided below: Leading clinical data in solid tumor CAR-T Colorectal cancer: 3rd line treatment, ~50% PR/PMR (8/16) in dose escalation trial Activity in additional solid tumor indication including thyroid and pancreas Significant market opportunity in colorectal cancer and other solid tumor cancers Lead program in colorectal cancer: Estimated 53,2001 deaths (#2 cancer death) in the U.S. in 2020 Platform technology for solid tumors, which comprise 91% of new cancer cases Strong global IP protection CoupledCAR®, ArmoredCAR®, and other ICT technologies protected by ~200 patents/patent applications globally, including for U.S., Europe, China and Japan

Our mission is to develop a superior vaccine platform to improve clinical outcomes for cancer patients.

Johns Hopkins Medicine is a governing structure for the University’s School of Medicine and the health system, coordinating their research, teaching, patient care, and related enterprises. The Johns Hopkins Hospital opened in 1889, followed four years later by the university’s School of Medicine, revolutionizing medical practice, teaching, and research in the United States. The hospital is now part of the Johns Hopkins Health System, which includes two other acute-care hospitals and additional integrated health-care delivery components, with a network of primary and specialty care practices throughout Maryland, outpatient care, long-term care, and home care. The Johns Hopkins University opened in 1876 as America’s first research university, founded for the express purpose of expanding knowledge and putting that knowledge to work for the good of humanity. Two Interconnected Institutions: Over the years, the University and Hospital have grown, and—sometimes jointly, sometimes separately—they have created affiliated organizations. The Johns Hopkins Institutions is a collective name for the University and the Johns Hopkins Health System. The Johns Hopkins University includes nine academic and research divisions, and numerous centers, institutes, and affiliated entities. Johns Hopkins Medicine is a governing structure for the University’s School of Medicine and the health system, coordinating their research, teaching, patient care, and related enterprises.

Johns Hopkins University is a higher education institution known for its research initiatives and academic programs.

KaloCyte, Inc., a preclinical biotech that has developed an artificial RBC substitute for use as a lifeline when blood is not available. We are located at the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark. KaloCyte’s offices and labs are sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was founded in 2016 by a distinguished team of Washington University in St. Louis researchers in physiology, bioengineering, and trauma care, with support from the BioGenerator Fundamentals program. KaloCyte has demonstrated preclinical safety and efficacy for ErythroMer, a shelf-stable, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by $14M in federal awards and $5M investor funding. ErythroMer is a first-in-class, bio-inspired nanoparticle-encapsulated human hemoglobin, which mimics the vital oxygen-carrying functionality of RBCs and can be freeze-dried for long-term storage. Erythromer’s synthetic outer membrane, small size and surface area allow for physiologically realistic gas exchange. The synthetic polymer shell is “immune-silent”, inert and carries no blood antigens, eliminating the need to type and cross-match as with stored blood. ErythroMer can be freeze-dried or “lyophilized”, for a much longer shelf life than stored blood. It is covered by issued U.S. patents that specify composition of matter, method of preparation, and use as an oxygen carrier.

Kennedy Krieger Institute is a healthcare organization that specializes in pediatric care, medical research, and rehabilitation services.

At Kolon TissueGene, we are developing advanced cell therapies to target various orthopedic diseases and degenerative disorders.

SeraCare, part of LGC's Clinical Diagnostics Division, enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only ensure the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents.

Lieber Institute for Brain Development is a research institute focused on advancing understanding of brain development and disorders.

Longhorn Vaccines and Diagnostics, LLC is a research company Headquartered out of 7272 Wisconsin Avenue Bethesda, MD 20814 United States. The R&D facility is at 19 Firstfield Rd Gaithersburg, MD 20878.

As a biopharmaceutical company, our team of dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our DART® bispecific and Fc Optimization platforms. These platforms are generally focused on the creation of antibodies, antibody derivatives, and antibody-like molecules for use as therapeutic agents. We currently have a pipeline of product candidates in human clinical testing, including seven immuno-oncology programs. Our product candidates and platforms have attracted partnerships with leading pharmaceutical and biotechnology companies around the globe.

At Magbio Genomics, we are dedicated to advancing genetic research with cutting-edge products designed to safeguard the integrity of bio-samples while efficiently isolating circulating biomarkers. Specializing in human genetic research, including cancer studies and non-invasive prenatal testing (NIPT), our innovative solutions empower researchers to unlock invaluable insights. At the heart of our operations lies our core platform, enabling seamless nucleic acid sequencing methods such as Sanger and Next Generation Sequencing (NGS) across both manual and automated workflows. Our commitment extends beyond product development; it's about facilitating quality data generation at an accelerated pace and an accessible cost. Driven by our corporate mission, we strive to empower our customers to achieve their research goals efficiently and effectively, propelling scientific discoveries forward with Magbio Genomics by their side.

Biopharmaceutical Company engaged in vaccine development against emerging viruses and biopharma CDMO manufacturing.

Founded in 1995, Meso Scale Discovery (MSD) is a global leader in the development, manufacture, and commercialization of innovative assays and instruments for the measurement of molecules in biological samples. MSD’s proprietary MULTI ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. MSD’s technology has been widely adopted by researchers in pharmaceutical companies, government institutions, universities, and clinical laboratories worldwide for its high sensitivity, excellent reproducibility, and wide dynamic range. Throughout its history, MSD has continued to evolve its technology platform to enable researchers to solve complex biological questions and, as the Company looks toward the future, it is expanding into clinical applications and the emerging fields of personalized medicine and companion diagnostics.

We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

National Institute of Standards and Technology is a government agency that sets standards, conducts research, and promotes innovation in technology and measurement.

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on X @neoimmunetech

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. Currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. The Company’s approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. The Company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies. The Company’s platform technology, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system. The dendritic cells are extracted from the body, loaded with tumor biomarkers or ‘‘antigens’’, thereby creating a personalized therapeutic vaccine. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. The Company’s lead product candidate is DCVax®-Brain which targets Glioblastoma Multiforme (‘‘GBM’’), the most lethal form of brain cancer. DCVax®-Brain has entered a Phase II FDA-allowed clinical trial, which is designed and powered as a pivotal trial (i.e. a trial from which a company may go directly to product approval). Following this trial, the Company anticipates filing a biologic license application (or ‘‘BLA’’) with the FDA for DCVax®-Brain. DCVax®-Prostate, which targets hormone independent (i.e. late stage) prostate cancer, has also been cleared by the FDA to commence a Phase III clinical trial, which is also designed and powered as a pivotal trial.

We’re focused on using our proven vaccine technology to protect health by developing our R&D assets and establishing partnerships. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our mission of ensuring broad access to our vaccines. It’s more than our job. It’s our passion. Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines

Nuo Therapeutics, Inc. is a biomedical company that develops and commercializes individualized wound care therapies that harness a patient’s innate regenerative ability to stimulate wound healing. The Company’s flagship product, Aurix is a biodynamic hematogel derived from the patient’s own platelets and plasma, which is used at the point-of-care to jumpstart the natural healing process in a broad range of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure injuries.

Based in Rockville, Maryland, OncoC4 is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.

Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships its CGTs to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.

OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome-wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collections and over 25,000 TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the largest offering of full-length human proteins expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens to develop protein assays for every human protein. In addition, OriGene offers unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation OriGene is committed to its mission to be “Your Gene Company”, supplying everything a researcher needs for gene-based research. Visit us at https://www.origene.com

OspreyBio is a newly launched and first gene-and-cell-therapy-centric biotools company. Our core principle is to "Think Multigenic". From tools to make multi-effector AAVs to 8-gene (or more) constructs, Osprey is expanding its portfolio of products related to building multigenes, delivering large DNA, and reducing manufacturing costs to bring us all into the future of gene and cell therapy.

Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent supports our partners in introducing 200 new products and manufacturing over 70 billion doses each year. Since becoming a publicly traded company in 2014, we have grown to become a community of approximately 19,000+ workers who support over 7,000 products for over 1,000 customers around the world. We share a common goal: to put patients first and help people around the world live better and healthier lives. Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. We have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging results. more products. better treatments. reliably supplied.™ Your talents, ideas, and passion are essential to our mission: to develop, manufacture, and supply products that help people live better, healthier lives. Join us! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s advanced technologies and collaboration with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help bring life-enhancing products to life. Grow with us. Be challenged. Make a personal impact. Visit https://careers.catalent.com/us/en to explore career opportunities

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

Primera Therapeutics is a company that provides patient-centric gene therapies targeting the causes of mitochondrial disorders. The company focuses on developing treatments for rare mitochondrial diseases for which there are no approved therapies. Primera Therapeutics is pioneering a first-in-class gene editing platform to cure genetic diseases.

We work exclusively on orphan drugs and advanced therapies providing biotech partners with an integrated suite of strategic and operational regulatory services. Our regulatory team brings over 100 combined years of industry and consulting experience in orphan drug regulations and development. Made up entirely of Ph.D./MS-level/MD, senior regulatory strategists and mechanics, and all the passion in the world, they lead programs to success. Our Clients are those looking for strategic and operational support; someone who can be eyes-on and hands-on their program as and when needed; someone to help them navigate this complex regulatory pathway, and help them to decide when and how to submit their orphan applications, applications for accelerated approvals, and interactions with the Agencies. We plan, formulate questions, write, review, and/or submit. ­ - Regulatory operations ­ - Strategy & Development ­- Medical Writing ­- Publishing

RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company focused on tissue protection, repair and regeneration. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. RegeneRx’s management team is focused on moving three distinct Tβ4-based drug candidates through the clinic: RGN-137, RGN-259 and RGN-352. RegeneRx also holds over 75 issued patents or patent applications worldwide in order to enable and protect multiple indications and applications for its product candidates. Currently, RegeneRx has active partnerships in three major territories: the U.S. and Canada, China, and Pan Asia. Our partners have been moving forward and making significant progress in each territory with RGN-259, our ophthalmic drug candidate, and are preparing to initiate their clinical trials programs. In each case, the cost of development is being borne by our partners with no financial obligation for RegeneRx. Patient accrual, treatment, and follow-up for the ophthalmic trials are relatively fast, as opposed to most other clinical efforts, so data is typically forthcoming in months after patients begin enrollment. We have other significant clinical assets to develop, primarily RGN-352 (injectable formulation of Tβ4 for cardiac and CNS/PNS disorders) in the U.S., Pan Asia, and Europe, and RGN-259 in the EU. With respect to RGN-259, our goal is to wait until Phase 3 is completed in the U.S. before moving into the EU with RGN-259 in order to maximize value for the EU market. We intend to continue to develop RGN-352, either by obtaining grants to fund a Phase IIa clinical trial in the cardiovascular or central nervous system fields or finding a suitable partner with the resources and capabilities to develop it as we have with RGN-259.

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.

Rise Therapeutics is developing targeted immunological-based biologics using a unique and proprietary oral delivery platform. The company develops unique, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity and cancer.

At RNAimmune, we use mRNA technology to help people live full and healthy lives. Our primary focus is development of vaccines against cancer and respiratory viruses. Our expertise in design and production of mRNA vaccines is supported by research and development efforts toward novel lipids, targeted delivery and antigen engineering. We collaborate with the world for the health of everyone.

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and exosome/extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and exosome production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type II Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under one year. RoosterBio is driven by our client's success and creating a world where safe and effective advanced therapies are rapidly developed and widely available on a global scale.

SalubrisBio was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in Gaithersburg, Maryland, SalubrisBio represents and reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market. SalubrisBio focuses exclusively on the discovery and global development of novel, biologic therapeutics. Salubris Pharmaceuticals is a publicly-traded company [002294:CH], founded in 1998, which has grown to achieve sales of >$750M USD in 2016. Salubris Pharmaceuticals is a fully-integrated drug development company. Headquartered in Shenzhen, China, Salubris Pharmaceuticals has over 3,000 employees working across R&D, regulatory, marketing and sales. Its marketed products include small molecule drugs in the cardiovascular, anti-allergy and anti-infective therapeutic areas. GeneKey Biotech Ltd. Co. (www.genekeybio.com), based in Chengdu, China, is the China-based biologics subsidiary of Salubris Pharmaceuticals. GeneKey Biotech has a robust portfolio of biosimilar and novel large molecule therapeutics in development in China. SalubrisBio maintains close cross-functional collaborations with GeneKey Biotech, leveraging resources including the expertise of >150 research scientists and large-scale manufacturing of up to 2000L scale.

Sanaria is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.

Revolutionizing cell therapy to address inflammatory diseases driven via neonatal cardiac progenitor cells and their secretomes.

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.

Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies. Our highly pure insulin-producing cells are micro-encapsulated through a proprietary technology that enables the function of human pancreas cells in type-1 diabetes models without the need for immuno-suppression. Seraxis intends to bring SR-01 to the clinic in order to provide a cure for the devastating disease of diabetes.

We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 25 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States. We market Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Kolon TissueGene is a biotechnology company that specializes in developing cell and gene therapy for osteoarthritis diseases.

Trophogen, Inc. is a biotechnology company founded in 2001 with series A funding from Toucan Capital, focusing on the development of high affinity glycoprotein hormone and related growth factor analogs for human and animal infertility as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers.

Uniformed Services University is a medical education institution that specializes in training healthcare professionals for military service.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.

Vita Therapeutics - We are a team of dedicated scientists striving to advance treatments in multiple indications in our cell therapy platform. Our mission is to utilize the power of genetics to deliver life-transformative cell therapies by unlocking the potential of engineered cellular medicine.

VLP Therapeutics, Inc. (VLPT) was established in 2013 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology. The company is headquartered in Gaithersburg, Maryland.

Zyngenia is a biotechnology company that develops highly specific, single molecule biotherapeutics targeting multiple physiologic pathways to treat complex diseases like cancer and inflammation.